Cargando…
Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis
BACKGROUND: although being central for the biology and druggability of hormone-receptor positive, HER2 negative metastatic breast cancer (MBC), ESR1 and PIK3CA mutations are simplistically dichotomized as mutated or wild type in current clinical practice. METHODS: The study analyzed a multi-institut...
Autores principales: | Gerratana, Lorenzo, Davis, Andrew A., Velimirovic, Marko, Clifton, Katherine, Hensing, Whitney L., Shah, Ami N., Dai, Charles S., Reduzzi, Carolina, D’Amico, Paolo, Wehbe, Firas, Medford, Arielle, Wander, Seth A., Gradishar, William J., Behdad, Amir, Puglisi, Fabio, Ma, Cynthia X., Bardia, Aditya, Cristofanilli, Massimo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546685/ https://www.ncbi.nlm.nih.gov/pubmed/37784176 http://dx.doi.org/10.1186/s13058-023-01718-0 |
Ejemplares similares
-
Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer
por: Davis, Andrew A., et al.
Publicado: (2022) -
Landscape of circulating tumour DNA in metastatic breast cancer
por: Davis, Andrew A., et al.
Publicado: (2020) -
Positive predictive value of ERBB2 copy number gain by tissue or circulating tumor DNA next-generation sequencing across advanced cancers
por: Shah, Ami N., et al.
Publicado: (2022) -
Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone
por: Cristofanilli, Massimo
Publicado: (2012) -
Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast Cancer
por: Gerratana, Lorenzo, et al.
Publicado: (2021)